Genocea Biosciences has named Chip Clark as chief business officer of the vaccine-focused biotech firm in Cambridge.
Clark most recently co-founded Rockville, Md.-based Vanda Pharmaceutical Inc., a pharmacogenetics firm where he served as chief business officer and helped secure more than $220 million in funding and landed a licensing deal with Novartis that brought in $200 million upfront, plus $265 million in milestone payments.
Prior to co-founding Vanda, Clark served as a principal at venture capital firm Care Capital LLC, which focused on biopharmaceutical investments. He earned a bachelor’s degree from Harvary University and a M.B.A. from The Wharton School at the University of Pennsylvania.
Founded in 2006, Genocea Biosciences is developing vaccines for Chlamydia trachomatis, Streptococcus pneumoniae, malaria and herpes simplex virus type 2. The company is led by president and CEO Mustapha Leavenworth Bakali and financially backed by investors Lux Capital Management, Polaris Venture Partners, SR One, the corporate venture arm of GlaxoSmithKline, Auriga Partners, Cycad Group, Morningside Ventures and Alexandria Real Estate Equities.